Prasugrel Therapy Duration and Management
Recommended Duration of Prasugrel Therapy
- The American College of Cardiology recommends that prasugrel should be continued for at least 12 months and up to 15 months in patients who have undergone percutaneous coronary intervention (PCI) unless the risk of bleeding outweighs the anticipated benefit 1, 2
- For patients receiving a drug-eluting stent (DES), prasugrel should be given for at least 12 months and up to 15 months, according to the American Heart Association guidelines 1, 2
- For patients receiving a bare metal stent (BMS), prasugrel should be given for at least 1 month and ideally up to 12 months, as recommended by the American College of Cardiology 1, 2
- The decision to continue prasugrel beyond 12 months may be considered on an individual basis, especially for high-risk patients such as those with diabetes or prior myocardial infarction, as suggested by the European Society of Cardiology 3, 4
Clinical Evidence Supporting Prasugrel Use
- Prasugrel significantly reduced stent thrombosis rates from 2.4% to 1.1% compared to clopidogrel, according to a study published in Circulation 5
Important Contraindications and Precautions
- The American Heart Association recommends that prasugrel is contraindicated in patients with a history of transient ischemic attack (TIA) or stroke 5
- For patients ≥75 years of age, prasugrel is generally not recommended due to increased risk of fatal and intracranial bleeding, except in high-risk situations (diabetes or prior MI), as advised by the American College of Cardiology 1, 2
- For patients weighing <60 kg, the American College of Cardiology suggests reducing maintenance dose to 5 mg daily (from standard 10 mg) due to increased exposure to active metabolite and higher bleeding risk 1, 2
Bleeding Risk Assessment
- Prasugrel is associated with a higher risk of bleeding compared to clopidogrel, with TIMI major hemorrhage observed in 2.4% of patients taking prasugrel vs. 1.8% with clopidogrel, according to a study published in Circulation 5
- Fatal bleeding was significantly higher with prasugrel (0.4%) compared to clopidogrel (0.1%), as reported in Circulation 5
- Body weight <60 kg is an additional risk factor for bleeding, as noted by the American Heart Association 2
Monitoring and Follow-up
- Patients should be counseled on the importance of compliance with dual antiplatelet therapy (DAPT), as recommended by the American College of Cardiology 3
- Regular assessment for bleeding complications is essential, according to the European Society of Cardiology 4